U.S. Markets closed
  • S&P Futures

    3,635.25
    +8.00 (+0.22%)
     
  • Dow Futures

    29,889.00
    +61.00 (+0.20%)
     
  • Nasdaq Futures

    12,193.25
    +41.00 (+0.34%)
     
  • Russell 2000 Futures

    1,852.10
    +7.50 (+0.41%)
     
  • Crude Oil

    46.01
    +0.30 (+0.66%)
     
  • Gold

    1,809.20
    +3.70 (+0.20%)
     
  • Silver

    23.44
    +0.08 (+0.36%)
     
  • EUR/USD

    1.1930
    +0.0011 (+0.0954%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.25
    -0.39 (-1.80%)
     
  • GBP/USD

    1.3391
    +0.0008 (+0.0629%)
     
  • USD/JPY

    104.3320
    -0.1080 (-0.1034%)
     
  • BTC-USD

    18,733.64
    -109.49 (-0.58%)
     
  • CMC Crypto 200

    367.48
    -3.03 (-0.82%)
     
  • FTSE 100

    6,391.09
    -41.08 (-0.64%)
     
  • Nikkei 225

    26,442.26
    +145.40 (+0.55%)
     

Adamas to Announce Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020

Adamas Pharmaceuticals, Inc.
·1 min read

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 third quarter financial results on Thursday, November 5, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Investor Conference Call and Webcast
The conference call can be accessed by dialing (844) 215-3280 for participants in the U.S. or Canada and (484) 747-6383 for international callers. All callers must provide the following Conference ID: 1578986. The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations and will be available for replay until December 5, 2020.

About Adamas Pharmaceuticals, Inc.
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Contact

Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
smathieson@adamaspharma.com

Investors:
Peter Vozzo
Managing Director, Westwicke
443-213-0505
peter.vozzo@westwicke.com